ImmuPharma remain focussed on achieving full regulatory approval of Lupuzor with US partner Avion
ImmuPharma plc (LON:IMM), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2019. Key Highlights (including post Period review)